AU2021344871A1 - Compositions and methods for the treatment of lipid-related disorders - Google Patents

Compositions and methods for the treatment of lipid-related disorders Download PDF

Info

Publication number
AU2021344871A1
AU2021344871A1 AU2021344871A AU2021344871A AU2021344871A1 AU 2021344871 A1 AU2021344871 A1 AU 2021344871A1 AU 2021344871 A AU2021344871 A AU 2021344871A AU 2021344871 A AU2021344871 A AU 2021344871A AU 2021344871 A1 AU2021344871 A1 AU 2021344871A1
Authority
AU
Australia
Prior art keywords
acid
formula
compound
pharmaceutical composition
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021344871A
Other languages
English (en)
Other versions
AU2021344871A9 (en
Inventor
Eran Blaugrund
Alon BLOOMENFELD
Sharon COHEN VERED
Racheli GUETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raziel Therapeutics Ltd
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of AU2021344871A1 publication Critical patent/AU2021344871A1/en
Publication of AU2021344871A9 publication Critical patent/AU2021344871A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021344871A 2020-09-16 2021-09-15 Compositions and methods for the treatment of lipid-related disorders Pending AU2021344871A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079195P 2020-09-16 2020-09-16
US63/079,195 2020-09-16
PCT/IB2021/000640 WO2022058795A1 (en) 2020-09-16 2021-09-15 Compositions and methods for the treatment of lipid-related disorders

Publications (2)

Publication Number Publication Date
AU2021344871A1 true AU2021344871A1 (en) 2023-05-25
AU2021344871A9 AU2021344871A9 (en) 2024-08-08

Family

ID=80776673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021344871A Pending AU2021344871A1 (en) 2020-09-16 2021-09-15 Compositions and methods for the treatment of lipid-related disorders

Country Status (7)

Country Link
US (1) US20230355584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213835A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506228A (cg-RX-API-DMAC7.html)
CN (1) CN116685316A (cg-RX-API-DMAC7.html)
AU (1) AU2021344871A1 (cg-RX-API-DMAC7.html)
IL (1) IL301325A (cg-RX-API-DMAC7.html)
WO (1) WO2022058795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof

Also Published As

Publication number Publication date
AU2021344871A9 (en) 2024-08-08
CN116685316A (zh) 2023-09-01
JP2024506228A (ja) 2024-02-13
WO2022058795A1 (en) 2022-03-24
US20230355584A1 (en) 2023-11-09
IL301325A (en) 2023-05-01
EP4213835A1 (en) 2023-07-26
EP4213835A4 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
JP7850665B2 (ja) 血管脂肪腫の処置のための組成物
CA3157869A1 (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
IE922181A1 (en) The use of sulphur-containing carboxylic acids to combat¹physiologically-induced excitatory disorders and diseases¹related thereto as well as allergic diseases and also the¹preparation of corresponding medicaments
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
US20180221406A1 (en) Therapeutic combinations of antiviral and anti-inflammatory therapies
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
EP2625180A2 (en) Porphyrin treatment of neurodegenerative diseases
HK40077772A (en) Compositions for the treatment of solid tumors
US20230159569A1 (en) Dual hdac6/proteasome inhibitors, and methods of use thereof
CA2073694A1 (en) 4,4' [9h-fluoren-9-ylidenebis (methylene)]-bispyrimidine for treating neurological disorders
EP4638450A1 (en) Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors
WO2019173506A1 (en) Cyclopentaimidazolones for the treatment of cancer

Legal Events

Date Code Title Description
SREP Specification republished